Commerce Bank Takes $1.90 Million Position in Repligen Corporation $RGEN

Commerce Bank acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 13,920 shares of the biotechnology company’s stock, valued at approximately $1,899,000.

A number of other large investors also recently bought and sold shares of the business. NewEdge Wealth LLC lifted its holdings in Repligen by 5.3% during the fourth quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock worth $244,000 after buying an additional 75 shares during the period. UMB Bank n.a. increased its holdings in shares of Repligen by 13.8% in the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 92 shares during the period. CANADA LIFE ASSURANCE Co raised its position in shares of Repligen by 0.3% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock worth $4,542,000 after acquiring an additional 100 shares in the last quarter. Coldstream Capital Management Inc. raised its position in shares of Repligen by 5.3% in the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock worth $326,000 after acquiring an additional 101 shares in the last quarter. Finally, Itau Unibanco Holding S.A. lifted its stake in shares of Repligen by 38.0% during the 4th quarter. Itau Unibanco Holding S.A. now owns 378 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 104 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Repligen Price Performance

NASDAQ RGEN opened at $181.69 on Wednesday. Repligen Corporation has a 1 year low of $100.99 and a 1 year high of $188.73. The company has a market cap of $10.25 billion, a price-to-earnings ratio of 248.89, a PEG ratio of 3.31 and a beta of 1.03. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The stock’s fifty day moving average price is $149.17 and its 200 day moving average price is $132.22.

Repligen (NASDAQ:RGEN) last released its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, topping analysts’ consensus estimates of $0.45 by $0.09. Repligen had a return on equity of 5.30% and a net margin of 5.29%.The firm had revenue of $204.13 million during the quarter, compared to the consensus estimate of $201.59 million. During the same quarter in the previous year, the company posted $0.26 earnings per share. The company’s revenue was up 11.9% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts forecast that Repligen Corporation will post 2.06 earnings per share for the current year.

Insider Activity

In other news, CFO Jason K. Garland sold 733 shares of the company’s stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $145.00, for a total value of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.60% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on RGEN shares. Wolfe Research assumed coverage on Repligen in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $145.00 price objective on the stock. JPMorgan Chase & Co. boosted their target price on shares of Repligen from $165.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Evercore reissued an “outperform” rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, August 13th. Finally, Barclays boosted their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research note on Wednesday, May 6th. Three investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Repligen presently has an average rating of “Buy” and a consensus price target of $166.43.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.